cab + rpv
cab + rpv: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: GH Research PLC (GHRS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| GH Research PLC (GHRS) | Phase 3 |
Clinical Trials (1)
An Open-label Study Evaluating the Pharmacokinetics (PK), Efficacy, Safety, and Tolerability of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) Intramuscular (IM) Administered Monthly and Every 2 Months in Virologically Suppressed HIV-1-Infected Adults With Severe Renal Impairment With or Without Hemodialysis (CAPRI)
Frequently asked questions
Who is developing cab + rpv?
cab + rpv is being developed by GH Research PLC.
How many clinical trials involve cab + rpv?
BioSniper tracks 1 clinical trial involving cab + rpv.
Analyze GH Research PLC & cab + rpv with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company